July 17, 2005
Adding Trastuzumab to Docetaxel Improves Survival in Metastatic Breast CancerTopics: Medicine
Trastuzumab (Herceptin) plus docetaxel (Taxotere) is better than docetaxel alone at improving the survival of patients with metastatic HER2-positive breast cancer, new research indicates. Moreover, there is little added toxicity when trastuzumab is given.
The findings, which appear in the Journal of Clinical Oncology for July 1, are based on a phase II study of 186 patients with HER2-positive metastatic breast cancer who were randomized to six cycles of docetaxel with or without trastuzumab, administered as first-line therapy.
(Comments later as time permits)
Posted by Hyscience at July 17, 2005 2:00 PM
Articles Related to Medicine: